Iovance Biotherapeutics Inc Asset Resilience Ratio
Iovance Biotherapeutics Inc asset resilience ratio. Iovance Biotherapeutics Inc (IOVA) has an Asset Resilience Ratio of 15.77% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Iovance Biotherapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Iovance Biotherapeutics Inc (2013–2024)
Asset resilience ratio of Iovance Biotherapeutics Inc from 2013 to 2024. This chart shows how Iovance Biotherapeutics Inc's Asset Resilience Ratio has changed over time. Read IOVA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Iovance Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Iovance Biotherapeutics Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $142.67 Million | 15.77% |
| Total Liquid Assets | $142.67 Million | 15.77% |
Asset Resilience Insights
- Good Liquidity Position: Iovance Biotherapeutics Inc maintains a healthy 15.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Iovance Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Iovance Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Iovance Biotherapeutics Inc Asset Resilience Ratio by Year (2013–2024)
Iovance Biotherapeutics Inc asset resilience ratio by year from 2013 to 2024. The table below shows the annual Asset Resilience Ratio data for Iovance Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 22.86% | $208.09 Million | $910.43 Million | +1.71pp |
| 2023-12-31 | 21.14% | $164.98 Million | $780.35 Million | -15.02pp |
| 2022-12-31 | 36.16% | $240.11 Million | $663.98 Million | -18.66pp |
| 2021-12-31 | 54.83% | $426.18 Million | $777.33 Million | -18.32pp |
| 2020-12-31 | 73.15% | $562.11 Million | $768.46 Million | -11.90pp |
| 2019-12-31 | 85.05% | $293.11 Million | $344.65 Million | +4.69pp |
| 2018-12-31 | 80.36% | $386.37 Million | $480.82 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $155.37 Million | -- |
| 2016-12-31 | 34.76% | $59.75 Million | $171.89 Million | -50.48pp |
| 2015-12-31 | 85.24% | $90.06 Million | $105.65 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $46.51 Million | -- |
| 2013-12-31 | 0.03% | $5.00K | $19.87 Million | -- |
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more